Skip to main content
Equibles

Robert Wong

Chief Accounting Officer

Cytokinetics Inc (CYTK)

Equibles does not estimate personal net worth.

Get an email with a short summary when Cytokinetics Inc publishes a filing, an earnings call transcript or a press release.

Get CYTK alerts

About Robert Wong

Robert Wong is recorded as Chief Accounting Officer at Cytokinetics Inc (CYTK). The newest filing on record that lists Robert Wong as Chief Accounting Officer at Cytokinetics Inc (CYTK) is dated April 8, 2024. Robert Wong has spoken on 17 earnings calls across 1 company, most recently for Cytokinetics Inc on May 8, 2024. Cytokinetics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cytokinetics Inc includes Robert Blum (CEO), Robert I. Blum (CEO and Board Member), John T. Henderson, M.D. (Chairman) and 7 others.

Robert Wong on recent calls

“We ended the quarter with approximately $634.3 million of cash on the balance sheet, which represents 2 years of forward cash runway, including capital we expect to be available to us under our deal with Royalty Pharma upon satisfaction of conditions.”
Chief Accounting Officer, Cytokinetics Inc Q1 FY2024 Earnings Call ·
“We ended the fourth quarter with $655.4 million in cash and investments, which included $162.9 million that we raised through the after-market equity vehicle in the quarter.”
Chief Accounting Officer, Cytokinetics Inc Q4 FY2023 Earnings Call ·
“We ended the third quarter with $554.7 million in cash and investments. During the quarter, we received a $50 million milestone payment from Royalty Pharma upon the start of ACACIA-HCM, which is treated as a liability on our balance sheet in accordance with GAAP.”
Chief Accounting Officer, Cytokinetics Inc Q3 FY2023 Earnings Call ·
“We ended the second quarter with $592.6 million in cash and investments. Our revenue in Q2 2023 came from Astellas and is the remaining amount due to us from their $12 million commitment associated with our conduct of COURAGE ALS.”
Chief Accounting Officer, Cytokinetics Inc Q2 FY2023 Earnings Call ·
“We ended the first quarter with approximately $704 million in cash and investments.”
Chief Accounting Officer, Cytokinetics Inc Q1 FY2023 Earnings Call ·

Affiliation history

  • Cytokinetics Inc (CYTK)

    Chief Accounting Officer

    Proxy statement

    Current

    Start not stated–present

    Last confirmed April 8, 2024

Company network

Leadership on record at Cytokinetics Inc

Recent activity

Show 5 earlier activities